Results 51 to 60 of about 3,679,356 (272)

DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells.

Molecules and Cells, 2021
We demonstrate that DNA hypomethylating agent (HMA) treatment can directly modulate the anti-tumor response and effector function of CD8+ T cells. In vivo HMA treatment promotes CD8+ T cell tumor infiltration and suppresses tumor growth via CD8+ T cell ...
Helen Loo Yau, E. Bell, Ilias Ettayebi, Felipe Campos de Almeida, Giselle M. Boukhaled, S. Y. Shen, D. Allard, B. Morancho, Sajid A. Marhon, Charles A. Ishak, I. Gonzaga, Tiago da Silva Medina, Rajat Singhania, A. Chakravarthy, Raymond Chen, P. Mehdipour, Sandra Pommey, C. Klein, G. Amarante-Mendes, David Roulois, J. Arribas, J. Stagg, D. Brooks, Daniel D. de Carvalho   +23 more
semanticscholar   +1 more source

Natural killer cell response to chemotherapy-stressed cancer cells: Role in tumor immunosurveillance. [PDF]

, 2017
Natural killer (NK) cells are innate cytotoxic lymphoid cells that actively prevent neoplastic development, growth, and metastatic dissemination in a process called cancer immunosurveillance.
Borrelli, Cristiana, Cippitelli, Marco, Fionda, Cinzia, Santoni, Angela, Soriani, Alessandra, Zingoni, Alessandra   +5 more
core   +1 more source

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Frontiers in Oncology, 2021
Decitabine and guadecitabine are hypomethylating agents (HMAs) that exert inhibitory effects against cancer cells. This includes stimulation of anti-tumor immunity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients. Treatment of
K. Wong, R. Hassan, N. Yaacob
semanticscholar   +1 more source

Novel therapeutic strategies: hypomethylating agents and beyond [PDF]

Hematology, 2012
Abstract The treatment of symptomatic and high-risk myelodysplastic syndrome (MDS) spans several therapeutic goals and options. Key to the successful therapy of these heterogeneous diseases is careful characterization and diagnosis, including clinical, cytogenetic, biological, and molecular evaluation of individual patients.
openaire   +2 more sources

Clinical Results of Hypomethylating Agents in AML Treatment [PDF]

Journal of Clinical Medicine, 2014
Epigenetic changes play an important role in the development of acute myeloid leukemia (AML). Unlike gene mutations, epigenetic changes are potentially reversible, which makes them attractive for therapeutic intervention. Agents that affect epigenetics are the DNA methyltransferase inhibitors, azacitidine and decitabine.
Cruijsen, Marjan, Lübbert, Michael, Wijermans, Pierre W., Huls, Gerwin   +3 more
openaire   +3 more sources

Angioimmunoblastic T‐cell lymphoma after acute myeloid leukemia: Alleged common pathogenesis. A case report and literature review

Clinical Case Reports, 2020
The genomic landscape of AITL is characterized by mutation of epigenetic modifiers. This gene expression pattern resembles myeloid diseases and shows a potential role for hypomethylating agents as possible therapy for AITL.
Isabel Iturrate, Javier Loscertales, Elena Fernández‐Ruiz, Patricia Muñoz, Consuelo López, Luciana del Campo, Cecilia Muñoz, Adrián Alegre   +7 more
doaj   +1 more source

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers [PDF]

, 2016
The azanucleosides azacitidine and decitabine are currently used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible for intensive chemotherapy but are also being explored in other ...
Buschbeck, Marcus, Diesch, Jeannine, Garz, Anne-Kathrin, Götze, Katharina S., Palau, Anna, Zwick, Anabel   +5 more
core   +2 more sources

The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer [PDF]

, 2014
PURPOSE: To investigate SGI-110 as a "chemosensitizer" in ovarian cancer and to assess its effects on tumor suppressor genes (TSG) and chemoresponsiveness-associated genes silenced by DNA methylation in ovarian cancer.
Azab, Mohammad, Choy, Gavin, Fang, Fang, Lyons, John, Matei, Daniela, Miller, David F. B., Munck, Joanne, Nephew, Kenneth P., Pawelczak, Katherine S., Pilrose, Jay, Tang, Jessica, Taverna, Pietro, Turchi, John J., VanderVere-Carozza, Pamela, Wagner, Michael, Wang, Yinu   +15 more
core   +1 more source

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting

Experimental Hematology & Oncology, 2023
Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R)
Xubo Gong, Yi Zhang, Xin He, Milad Moloudizargari, Teng Yu, Lin Wang, Weiwei Liu, Lan Jin, Huiying Xu, Yang Xu, Zhihua Tao, Wenbin Qian   +11 more
doaj   +1 more source

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

HemaSphere, 2021
Supplemental Digital Content is available in the text. Hypomethylating agents (HMAs) in combination with venetoclax have been widely adopted as the standard of care for patients who cannot tolerate induction chemotherapy and for patients who have ...
J. Feld, D. Tremblay, Mikaela Dougherty, Tina Czaplinska, Gillian Sanchez, C. Brady, M. Kremyanskaya, M. Bar‐Natan, A. Keyzner, B. Marcellino, J. Gabrilove, S. Navada, L. Silverman, S. E. El Jamal, J. Mascarenhas, A. Shih   +15 more
semanticscholar   +1 more source